Skip to main content
Top

15-04-2024 | Pleural Mesothelioma | Original Research Article

Development of Patient and Caregiver Conceptual Models Investigating the Health-Related Quality of Life Impacts of Malignant Pleural Mesothelioma

Authors: Adam E. J. Gibson, Waqas Ahmed, Louise Longworth, Bryan Bennett, Melinda Daumont, Liz Darlison

Published in: The Patient - Patient-Centered Outcomes Research

Login to get access

Abstract

Background

Malignant pleural mesothelioma (MPM) is a rare and usually fatal malignancy frequently linked to occupational asbestos exposures and associated with poor prognosis and considerable humanistic burden. The study aimed to develop conceptual models of the health-related quality of life (HRQoL) impact on patients with and receiving treatment for MPM, and the burden on their caregivers.

Methods

This multi-country study (Australia and United Kingdom) adopted a qualitative methodology to conduct semi-structured, independent interviews with people with MPM (n = 26), current caregivers (n = 20), and caregivers of people who had recently died because of MPM (n = 4). Participants were recruited using a purposive sampling approach and interviews conducted via telephone between January 2021 and January 2022. Transcripts were analysed using thematic analysis and used to construct conceptual models.

Results

Patient analysis yielded four overarching themes: (1) debilitating burden of breathlessness and fatigue; (2) physical mesothelioma symptoms experienced by patients; (3) distress of MPM on the self and family; and (4) treatment is worth ‘having a go’ despite the potential impact on symptoms. Caregiver analysis yielded five core themes: (1) daily life limited by caregiving duties; (2) emotional well-being and the need for support; (3) the relational role shift to caregiver; (4) time spent providing care negatively impacts work and productivity; and (5) positive aspects and outcomes of caregiving.

Conclusions

This study highlights the substantial daily and emotional HRQoL impact that MPM symptoms have on patients and caregivers. Both groups reduced work, productivity, and social and leisure activities. There was evidence of positive HRQoL impacts as a result of immunotherapy and radiotherapy, but less for chemotherapy. Caregiver impacts were intensified during the end-of-life period and persisted following patient death. Evident is a need for increased psychological support, information, and advice for caregivers, increased during the end-of-life period.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hamra G, Loomis D, Dement J. Examining the association of lung cancer and highly correlated fibre size-specific asbestos exposures with a hierarchical Bayesian model. Occup Environ Med. 2014;71:353–7.CrossRefPubMed Hamra G, Loomis D, Dement J. Examining the association of lung cancer and highly correlated fibre size-specific asbestos exposures with a hierarchical Bayesian model. Occup Environ Med. 2014;71:353–7.CrossRefPubMed
2.
go back to reference Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy, and future of a man-made epidemic. Eur Respir Rev. 2017;24:115–31.CrossRef Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy, and future of a man-made epidemic. Eur Respir Rev. 2017;24:115–31.CrossRef
3.
go back to reference Van Zandwijk N, Clarke, C., Henderson, D., Musk, W., Fong, K, Penman, A. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254-E307. Van Zandwijk N, Clarke, C., Henderson, D., Musk, W., Fong, K, Penman, A. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254-E307.
4.
go back to reference Ettinger D. NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. Off J Natl Comprehen Cancer Netw. 2016;14(7):825-36. Ettinger D. NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. Off J Natl Comprehen Cancer Netw. 2016;14(7):825-36.
5.
go back to reference Cavone D, Caputi A, De Maria L, Cannone ESS, Mansi F, Vimercati L. Epidemiology of mesothelioma. Environments 2019;6(7):76. Cavone D, Caputi A, De Maria L, Cannone ESS, Mansi F, Vimercati L. Epidemiology of mesothelioma. Environments 2019;6(7):76.
6.
go back to reference Bianchi C, Bianchi T. Global mesothelioma epidemic: trend and features. Indian J Occupat Environ Med. 2014;18(2):82-8. Bianchi C, Bianchi T. Global mesothelioma epidemic: trend and features. Indian J Occupat Environ Med. 2014;18(2):82-8.
8.
go back to reference Musk ABW, de Klerk N, Brims FJ. Mesothelioma in Australia: a review. Med J Aust. 2017;207(10):449–52.CrossRefPubMed Musk ABW, de Klerk N, Brims FJ. Mesothelioma in Australia: a review. Med J Aust. 2017;207(10):449–52.CrossRefPubMed
9.
go back to reference Shah N, Williams, A. Surviving the asbestos epidemic. Insurance Digest (European). 2001:14-8. Shah N, Williams, A. Surviving the asbestos epidemic. Insurance Digest (European). 2001:14-8.
11.
go back to reference Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375-86. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375-86.
12.
go back to reference Nakajima E, Vellanki, J., Larkins, E., Chatterjee, Mishra-Kalyani, PS, Donoghue, M. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446-51. Nakajima E, Vellanki, J., Larkins, E., Chatterjee, Mishra-Kalyani, PS, Donoghue, M. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446-51.
13.
go back to reference EMA. Assessment report: ipilimumab/nivolumab (EMA/CHMP/260350/2021). EMA; 2021:1–164. EMA. Assessment report: ipilimumab/nivolumab (EMA/CHMP/260350/2021). EMA; 2021:1–164.
14.
go back to reference PBS. Submission: nivolumab plus ipilimumab. Retrieved from: https://wwwpbsgovau/industry/listing/elements/pbac-meetings/psd/2021-03/files/nivolumab-plus-ipilimumab-psd-mar-2021docx. 24th June 2022. 2021:1-42. PBS. Submission: nivolumab plus ipilimumab. Retrieved from: https://​wwwpbsgovau/​industry/​listing/​elements/​pbac-meetings/​psd/​2021-03/​files/​nivolumab-plus-ipilimumab-psd-mar-2021docx.​ 24th June 2022. 2021:1-42.
15.
go back to reference Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis. 2016;10(3):275–88.CrossRefPubMedPubMedCentral Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis. 2016;10(3):275–88.CrossRefPubMedPubMedCentral
16.
go back to reference Girgis S, Smith AB, Lamber S, Waller A, Girgis A. ‘It sort of hit me like a baseball bat between the eyes’: a qualitative study of the psychosocial experiences of mesothelioma patients and carers. Support Care Cancer. 2019;27(2):631–8.CrossRefPubMed Girgis S, Smith AB, Lamber S, Waller A, Girgis A. ‘It sort of hit me like a baseball bat between the eyes’: a qualitative study of the psychosocial experiences of mesothelioma patients and carers. Support Care Cancer. 2019;27(2):631–8.CrossRefPubMed
17.
go back to reference Sturges J, Hanrahan KJ. Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107–18.CrossRef Sturges J, Hanrahan KJ. Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107–18.CrossRef
19.
go back to reference Clarke V, Braun, V. Thematic analysis. In: Michalos AC (ed) Encyclopaedia of quality of life and well-being research. Springer, Dordrecht. 2014. Clarke V, Braun, V. Thematic analysis. In: Michalos AC (ed) Encyclopaedia of quality of life and well-being research. Springer, Dordrecht. 2014.
20.
go back to reference Coast J. Qualitative methods for health economics: rowan and littlefield international; 2017. Coast J. Qualitative methods for health economics: rowan and littlefield international; 2017.
21.
go back to reference Silverman D. Doing qualitative research: a practical handbook. London: SAGE; 2010. Silverman D. Doing qualitative research: a practical handbook. London: SAGE; 2010.
22.
go back to reference Guest G, Bunce A, Johnson L. An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef Guest G, Bunce A, Johnson L. An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef
23.
go back to reference Moore S, Darlison L, Tod AM. Living with mesothelioma: a literture review European. J Cancer Care. 2010;19:458–68.CrossRef Moore S, Darlison L, Tod AM. Living with mesothelioma: a literture review European. J Cancer Care. 2010;19:458–68.CrossRef
24.
go back to reference Brims F, Gunatilake, S., Lawrie, I., Marshall, L., Fogg, C, Chauhan, AJ. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74:354-61. Brims F, Gunatilake, S., Lawrie, I., Marshall, L., Fogg, C, Chauhan, AJ. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74:354-61.
25.
go back to reference Arber A, Spener L. ‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma. Psychooncology. 2013;22(7):1528–33.CrossRefPubMed Arber A, Spener L. ‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma. Psychooncology. 2013;22(7):1528–33.CrossRefPubMed
26.
go back to reference Hughes N, Arber A. The lived eperience of patients with pleural mesothelioma. Int J Palliat Nurs. 2009;14(2):66–71.CrossRef Hughes N, Arber A. The lived eperience of patients with pleural mesothelioma. Int J Palliat Nurs. 2009;14(2):66–71.CrossRef
27.
go back to reference Ejegi-Memeg S, Sherborne, V., Harrison, M., Taylor, B., Senek, M, Gardiner, C. Patients’ and informal carers’ experience of living with mesothelioma: a systematic rapid review and synthesis of the literature. Eur J Oncol Nurs. 2022;58:102122. Ejegi-Memeg S, Sherborne, V., Harrison, M., Taylor, B., Senek, M, Gardiner, C. Patients’ and informal carers’ experience of living with mesothelioma: a systematic rapid review and synthesis of the literature. Eur J Oncol Nurs. 2022;58:102122.
28.
go back to reference Harrison M, Gardiner C, Taylor B, Ejegi-Memeh S, Darlison L. Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: an integrative systematic review. Palliat Med. 2021;35(6):1039–51.CrossRefPubMedPubMedCentral Harrison M, Gardiner C, Taylor B, Ejegi-Memeh S, Darlison L. Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: an integrative systematic review. Palliat Med. 2021;35(6):1039–51.CrossRefPubMedPubMedCentral
29.
go back to reference Warby A, Dhillon HM, Kao S, Vardy JL. A survey of patient and caregiver experience with malignant pleural mesothelioma. Support Care Cancer. 2019;27:4675–86.CrossRefPubMed Warby A, Dhillon HM, Kao S, Vardy JL. A survey of patient and caregiver experience with malignant pleural mesothelioma. Support Care Cancer. 2019;27:4675–86.CrossRefPubMed
30.
go back to reference Henson K, Wickramasinghe B, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. 2019;76(1):51–60.CrossRefPubMed Henson K, Wickramasinghe B, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. 2019;76(1):51–60.CrossRefPubMed
Metadata
Title
Development of Patient and Caregiver Conceptual Models Investigating the Health-Related Quality of Life Impacts of Malignant Pleural Mesothelioma
Authors
Adam E. J. Gibson
Waqas Ahmed
Louise Longworth
Bryan Bennett
Melinda Daumont
Liz Darlison
Publication date
15-04-2024
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-024-00690-x
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.